Our plant technology offers dramatic scalability and economic advantages compared to existing production methods. We believe that these same advantages which drive our pharmaceutical opportunities also open new non-pharmaceutical markets in the areas of agricultural biotechnology, nutritional supplements and personal care ingredients. Our technology uses the natural manufacturing advantages of safflower to produce, extract and purify high-value, high-volume products from plants as an alternative to the traditional fermentation-based processes used today. We believe that this technology will produce a cost-effective source of pharmaceutical proteins which could provide access to life-saving therapies to underserved markets in Asia and the developing world. Thanks to our strong leadership we re already seeing positive results. Our plant-derived insulin is on the verge of entering clinical trials and as such, is one step closer to being engaged in a partnership. Our cardiovascular innovation, Apo AI is currently in preclinical testing, the results from which could attract significant interest from pharmaceutical companies. While these two products represent long-term success, in the short-term, our subsidiary Botaneco and its in-market and growing line-up of personal care products is delivering value.
SemBioSys Genetics is Calgary-based company (Alberta, Canada) with a phone number 4032505424. Our data show that the company is located at the address: 2985 23rd Avenue Northeast 110. The company has a web site: www.sembiosys.com.
Unfortunately сompany staff has not yet provided of company's activities, mission and detailed description.